You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Investigational Drug Information for IPI-549


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug IPI-549?

IPI-549 is an investigational drug.

There have been 5 clinical trials for IPI-549. The most recent clinical trial was a Phase 1 trial, which was initiated on March 6th 2020.

The most common disease conditions in clinical trials are Triple Negative Breast Neoplasms, Carcinoma, and Head and Neck Neoplasms. The leading clinical trial sponsors are Infinity Pharmaceuticals, Inc., Arcus Biosciences, Inc., and The V Foundation for Cancer Research.

There are six US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for IPI-549
TitleSponsorPhase
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell CarcinomaThe V Foundation for Cancer ResearchPhase 2
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell CarcinomaEzra CohenPhase 2
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)Roche Pharma AGPhase 2

See all IPI-549 clinical trials

Clinical Trial Summary for IPI-549

Top disease conditions for IPI-549
Top clinical trial sponsors for IPI-549

See all IPI-549 clinical trials

US Patents for IPI-549

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
IPI-549 ⤷  Try a Trial Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same Infinity Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try a Trial
IPI-549 ⤷  Try a Trial Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try a Trial
IPI-549 ⤷  Try a Trial Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try a Trial
IPI-549 ⤷  Try a Trial Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try a Trial
IPI-549 ⤷  Try a Trial Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try a Trial
IPI-549 ⤷  Try a Trial Heterocyclic compounds and uses thereof Infinity Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for IPI-549

Drugname Country Document Number Estimated Expiration Related US Patent
IPI-549 Australia AU2016322552 2035-09-14 ⤷  Try a Trial
IPI-549 Canada CA2998469 2035-09-14 ⤷  Try a Trial
IPI-549 China CN108349985 2035-09-14 ⤷  Try a Trial
IPI-549 China CN114230571 2035-09-14 ⤷  Try a Trial
IPI-549 European Patent Office EP3350183 2035-09-14 ⤷  Try a Trial
IPI-549 Hong Kong HK1261923 2035-09-14 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.